
Oliver N Keene

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7189249/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease. New England Journal of Medicine, 2004, 351, 1521-1531.	27.0	2,135
2	Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet, The, 2012, 380, 651-659.	13.7	1,849
3	Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. New England Journal of Medicine, 2014, 371, 1198-1207.	27.0	1,807
4	Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. New England Journal of Medicine, 2014, 371, 1189-1197.	27.0	1,331
5	Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections. New England Journal of Medicine, 1997, 337, 874-880.	27.0	746
6	Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes. New England Journal of Medicine, 2004, 350, 11-20.	27.0	658
7	Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine,the, 2016, 4, 549-556.	10.7	433
8	The log transformation is special. Statistics in Medicine, 1995, 14, 811-819.	1.6	412
9	Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatric Infectious Disease Journal, 2000, 19, 410-417.	2.0	246
10	Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party. Drug Information Journal, 1995, 29, 1039-1048.	0.5	232
11	Biomarkers for severe eosinophilic asthma. Journal of Allergy and Clinical Immunology, 2017, 140, 1509-1518.	2.9	180
12	Diagnosis of Influenza in the Community. Archives of Internal Medicine, 2001, 161, 2116.	3.8	153
13	Zanamivir for the Treatment of Influenza A and B Infection in High-Risk Patients. Archives of Internal Medicine, 2001, 161, 212.	3.8	134
14	An Oral Inhibitor of p38 MAP Kinase Reduces Plasma Fibrinogen in Patients With Chronic Obstructive Pulmonary Disease. Journal of Clinical Pharmacology, 2012, 52, 416-424.	2.0	99
15	Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study. Pharmaceutical Statistics, 2007, 6, 89-97.	1.3	98
16	Impact of Zanamivir on Antibiotic Use for Respiratory Events Following Acute Influenza in Adolescents and Adults. Archives of Internal Medicine, 2000, 160, 3234.	3.8	96
17	Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. European Respiratory Journal, 2008, 32, 17-24.	6.7	87
18	Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A <i>Post Hoc</i> Analysis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1308-1312.	5.6	87

OLIVER N KEENE

#	Article	IF	CITATIONS
19	Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. Journal of Allergy and Clinical Immunology, 2017, 139, 1167-1175.e2.	2.9	78
20	Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 980-986.e1.	3.8	60
21	Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology, 2015, 136, 825-826.	2.9	46
22	Inhaled Zanamivir Versus Rimantadine for the Control of Influenza in a Highly Vaccinated Long-term Care Population. Journal of the American Medical Directors Association, 2005, 6, 359-366.	2.5	45
23	Missing data sensitivity analysis for recurrent event data using controlled imputation. Pharmaceutical Statistics, 2014, 13, 258-264.	1.3	33
24	Estimands: discussion points from the PSI estimands and sensitivity expert group. Pharmaceutical Statistics, 2017, 16, 6-11.	1.3	32
25	Alternatives to the hazard ratio in summarizing efficacy in time-to-event studies: an example from influenza trials. Statistics in Medicine, 2002, 21, 3687-3700.	1.6	27
26	Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert Group. Pharmaceutical Statistics, 2006, 5, 61-66.	1.3	27
27	Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma. Allergy, Asthma and Clinical Immunology, 2019, 15, 53.	2.0	25
28	From DREAM to REALITIâ€A and beyond: Mepolizumab for the treatment of eosinophilâ€driven diseases. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 778-797.	5.7	25
29	Methods for therapeutic trials in COPD: lessons from the TORCH trial. European Respiratory Journal, 2009, 34, 1018-1023.	6.7	24
30	Evaluation of different metrics as indirect measures of rate of drug absorption from extended release dosage forms at steady-state. Pharmaceutical Research, 1995, 12, 103-107.	3.5	22
31	Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 874-882.e4.	3.8	19
32	Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1121-1132.e7.	3.8	19
33	Intentâ€toâ€treat analysis in the presence of offâ€treatment or missing data. Pharmaceutical Statistics, 2011, 10, 191-195.	1.3	16
34	Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing. Pharmaceutical Statistics, 2021, 20, 551-562.	1.3	15
35	What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD. Pharmaceutical Statistics, 2020, 19, 370-387.	1.3	14
36	Why ITT analysis is not always the answer for estimating treatment effects in clinical trials. Contemporary Clinical Trials, 2021, 108, 106494.	1.8	12

OLIVER N KEENE

#	Article	IF	CITATIONS
37	Subgroups: Time to Go Back to Basic Statistical Principles?. Journal of Biopharmaceutical Statistics, 2014, 24, 58-71.	0.8	9
38	Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of ≥150–300â€⁻cells/μL. Respiratory Medicine, 2019, 151, 139-141.	2.9	9
39	Treatment policy estimands for recurrent event data using data collected after cessation of randomised treatment. Pharmaceutical Statistics, 2019, 18, 85-95.	1.3	8
40	Strategies for composite estimands in confirmatory clinical trials: Examples from trials in nasal polyps and steroid reduction. Pharmaceutical Statistics, 2019, 18, 78-84.	1.3	8
41	Clinical Efficacy of Inhaled Zanamivir for the Treatment of Patients with Influenza B Virus Infection. Clinical Drug Investigation, 2000, 20, 223-228.	2.2	7
42	Number needed to treat in COPD: exacerbations versus pneumonias. Thorax, 2013, 68, 882.1-882.	5.6	5
43	Use of generalized estimating equations in a trial in influenza to explore treatment effects over time. Pharmaceutical Statistics, 2004, 3, 281-287.	1.3	4
44	Glaxo's Experience of Different Absorption Rate Metrics of Immediate Release and Extended Release Dosage Forms. Drug Information Journal, 1995, 29, 821-840.	0.5	3
45	Temporal Clustering of Exacerbations in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 984-985.	5.6	1
46	Statistical resource needs to be increased in the European regulatory agencies. Pharmaceutical Statistics, 2011, 10, 87-88.	1.3	1
47	Number needed to treat: enigmatic results for exacerbations in COPD. European Respiratory Journal, 2016, 47, 353-354.	6.7	1
48	Estimation of a treatment policy estimand for time to event data using data collected post discontinuation of randomised treatment. Pharmaceutical Statistics, 2022, 21, 612-624.	1.3	1
49	Design and analysis of trials with rare outcomes: Examples from trials in herpes transmission and influenza prophylaxis. Contemporary Clinical Trials, 2005, 26, 311-322.	1.8	0
50	Comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma [Respir Med 2020]. Respiratory Medicine, 2022, 191, 106065.	2.9	0
51	Subgroup Analysis: A View from Industry. Emerging Topics in Statistics and Biostatistics, 2020, , 309-330.	0.1	0
52	Inhaled Zanamivir Versus Rimantadine for the Control of Influenza in a Highly Vaccinated Long-term Care Population. Journal of the American Medical Directors Association, 2005, 6, 359???366.	2.5	0